Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

1,120 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,120 results

Testing effectiveness (Phase 2)UnknownNCT00006114
What this trial is testing

Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group
Testing effectiveness (Phase 2)Study completedNCT00887458
What this trial is testing

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Who this might be right for
Prostate Cancer
Johns Hopkins University 46
Not applicableUnknownNCT01590498
What this trial is testing

Radiotherapy vs Observation for CRPC

Who this might be right for
Hormone Refractory Prostate Cancer
Zhengzhou University 2,000
Not applicableStudy completedNCT02353715
What this trial is testing

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

Who this might be right for
Prostate Cancer
Duke University 38
Testing effectiveness (Phase 2)Study completedNCT01519414
What this trial is testing

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more
National Cancer Institute (NCI) 78
Early research (Phase 1)Ended earlyNCT04249947
What this trial is testing

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Who this might be right for
Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more
Poseida Therapeutics, Inc. 40
Testing effectiveness (Phase 2)Study completedNCT02344017
What this trial is testing

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Orion Corporation, Orion Pharma 23
Early research (Phase 1)Study completedNCT02202447
What this trial is testing

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Who this might be right for
Prostate Cancer
Endocyte 40
Not applicableStudy completedNCT06461689
What this trial is testing

Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Central Hospital, Nancy, France 80
Large-scale testing (Phase 3)Looking for participantsNCT07213674
What this trial is testing

Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 750
Testing effectiveness (Phase 2)Study completedNCT00895310
What this trial is testing

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Who this might be right for
Prostate Cancer
University of California, Davis 30
Early research (Phase 1)Active Not RecruitingNCT04898634
What this trial is testing

JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 216
Early research (Phase 1)Ended earlyNCT02478125
What this trial is testing

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Early research (Phase 1)WithdrawnNCT02396368
What this trial is testing

Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate CancerBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Study completedNCT01692262
What this trial is testing

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Who this might be right for
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),Efficacy,Safety and Tolerability,+3 more
AstraZeneca 59
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Testing effectiveness (Phase 2)Ended earlyNCT00861471
What this trial is testing

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03787680
What this trial is testing

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 49
Testing effectiveness (Phase 2)Study completedNCT01795703
What this trial is testing

Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Who this might be right for
Prostate Cancer
Janssen Research & Development, LLC 47
Early research (Phase 1)Not Yet RecruitingNCT06866795
What this trial is testing

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Geode Therapeutics Inc. 42
Next Page